[Unresectable combined hepatocellular-cholangiocellular carcinoma treated with transcatheter arterial chemoembolization and gemcitabine: a case study].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Japanese Society Of Gastroenterology Country of Publication: Japan NLM ID: 2984683R Publication Model: Print Cited Medium: Print ISSN: 0446-6586 (Print) Linking ISSN: 04466586 NLM ISO Abbreviation: Nihon Shokakibyo Gakkai Zasshi Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tokyo : Japanese Society Of Gastroenterology
    • Subject Terms:
      Chemoembolization, Therapeutic*; Antimetabolites, Antineoplastic/*therapeutic use ; Bile Duct Neoplasms/*therapy ; Carcinoma, Hepatocellular/*therapy ; Cholangiocarcinoma/*therapy ; Deoxycytidine/*analogs & derivatives ; Liver Neoplasms/*therapy; Aged ; Bile Ducts, Intrahepatic ; Combined Modality Therapy ; Deoxycytidine/therapeutic use ; Female ; Humans ; Treatment Outcome ; Gemcitabine
    • Abstract:
      A 76-year-old female was referred to our hospital because of liver dysfunction. Abdominal contrasted computed tomography (CT) revealed a tumor of 7.5cm in the hepatic hilar area. Based on the biopsy, the tumor was diagnosed by as combined hepatocellular-cholangiocellular carcinoma (with stem-cell features). The tumor was considered unresectable;hence, the patient underwent transcatheter arterial chemoembolization (TACE). However, a CT scan revealed the treatment to be ineffective. Subsequently, systemic gemcitabine (GEM) chemotherapy was administered and tumor shrinkage was observed with reperfusion of the umbilical portion of the left portal vein. The patient's condition is currently stable 17 months after diagnosis, with no tumor regrowth on account of repeated TACE and GEM therapy. The present case of unresectable combined hepatocellular-cholangiocellular carcinoma was successfully treated using TACE and systemic GEM chemotherapy.
    • Accession Number:
      0 (Antimetabolites, Antineoplastic)
      0W860991D6 (Deoxycytidine)
      0 (Gemcitabine)
    • Publication Date:
      Date Created: 20181212 Date Completed: 20190426 Latest Revision: 20221207
    • Publication Date:
      20240829
    • Accession Number:
      10.11405/nisshoshi.115.1069
    • Accession Number:
      30531113